Liver transplantation for HBV-related disease under immunosuppression with tacrolimus: an experience with 78 consecutive cases.

O. Bronsther, S. Ersoz, M. Tugcu, B. Eghtesad, Ahmet Gurakar, D. H. Van Thiel

Research output: Contribution to journalArticle

Abstract

Hepatitis B viral liver disease (HBVLD) is a major worldwide health problem. It is estimated over 300 million people have had hepatitis B virus infection and that one-third of these have chronic HBVLD. Little effective therapy exists for HBVLD even though high dose interferon (IFN) has been advocated. For those who either are untreated or do not respond to IFN, HBVLD is steadily progressive and orthotopic liver transplantation (OLTx) is the only available therapy. Until quite recently, all OLTx recipients received cyclosporine (CyA) and prednisone. The consequence of OLTx for HBV disease in individuals immunosuppressed with tacrolimus has not previously been reported. A total of 78 consecutive patients with HBV-related liver diseases who were transplanted between January 1, 1990, and December 31, 1991, and treated with tacrolimus were studied. The clinical records of these patients were reviewed retrospectively. HBV disease recurrence was documented with serologic and histologic methods. As of April 1, 1993, 57 of 78 (73%) of the patients were still alive. Thirty-one of the alive patients have documented HBV recurrence. Eighteen of these 31 patients, however, have normal liver function. With a median follow-up of 24 months, 8 patients (10.9%) have died of recurrent HBVLD. Seven of 8 patients, who preoperatively were HBeAg+, developed recurrence and 4 of these patients have already died of recurrence. Patients who were HBsAg+ rarely recurred (1 of 16 patients). The use of HBIG did not prevent recurrence.(ABSTRACT TRUNCATED AT 250 WORDS)

Original languageEnglish (US)
Pages (from-to)103-108
Number of pages6
JournalJournal - Oklahoma State Medical Association
Volume88
Issue number3
StatePublished - Mar 1995
Externally publishedYes

Fingerprint

Tacrolimus
Liver Transplantation
Immunosuppression
Virus Diseases
Liver Diseases
Hepatitis B
Recurrence
Interferons
Hepatitis B e Antigens
Chronic Hepatitis B
Hepatitis B Surface Antigens
Prednisone
Hepatitis B virus
Cyclosporine
Liver

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Liver transplantation for HBV-related disease under immunosuppression with tacrolimus : an experience with 78 consecutive cases. / Bronsther, O.; Ersoz, S.; Tugcu, M.; Eghtesad, B.; Gurakar, Ahmet; Van Thiel, D. H.

In: Journal - Oklahoma State Medical Association, Vol. 88, No. 3, 03.1995, p. 103-108.

Research output: Contribution to journalArticle

@article{9a4a3ab06348457da459fd3c0a59fbc4,
title = "Liver transplantation for HBV-related disease under immunosuppression with tacrolimus: an experience with 78 consecutive cases.",
abstract = "Hepatitis B viral liver disease (HBVLD) is a major worldwide health problem. It is estimated over 300 million people have had hepatitis B virus infection and that one-third of these have chronic HBVLD. Little effective therapy exists for HBVLD even though high dose interferon (IFN) has been advocated. For those who either are untreated or do not respond to IFN, HBVLD is steadily progressive and orthotopic liver transplantation (OLTx) is the only available therapy. Until quite recently, all OLTx recipients received cyclosporine (CyA) and prednisone. The consequence of OLTx for HBV disease in individuals immunosuppressed with tacrolimus has not previously been reported. A total of 78 consecutive patients with HBV-related liver diseases who were transplanted between January 1, 1990, and December 31, 1991, and treated with tacrolimus were studied. The clinical records of these patients were reviewed retrospectively. HBV disease recurrence was documented with serologic and histologic methods. As of April 1, 1993, 57 of 78 (73{\%}) of the patients were still alive. Thirty-one of the alive patients have documented HBV recurrence. Eighteen of these 31 patients, however, have normal liver function. With a median follow-up of 24 months, 8 patients (10.9{\%}) have died of recurrent HBVLD. Seven of 8 patients, who preoperatively were HBeAg+, developed recurrence and 4 of these patients have already died of recurrence. Patients who were HBsAg+ rarely recurred (1 of 16 patients). The use of HBIG did not prevent recurrence.(ABSTRACT TRUNCATED AT 250 WORDS)",
author = "O. Bronsther and S. Ersoz and M. Tugcu and B. Eghtesad and Ahmet Gurakar and {Van Thiel}, {D. H.}",
year = "1995",
month = "3",
language = "English (US)",
volume = "88",
pages = "103--108",
journal = "The Journal of the Oklahoma State Medical Association",
issn = "0030-1876",
publisher = "Oklahoma State Medical Association",
number = "3",

}

TY - JOUR

T1 - Liver transplantation for HBV-related disease under immunosuppression with tacrolimus

T2 - an experience with 78 consecutive cases.

AU - Bronsther, O.

AU - Ersoz, S.

AU - Tugcu, M.

AU - Eghtesad, B.

AU - Gurakar, Ahmet

AU - Van Thiel, D. H.

PY - 1995/3

Y1 - 1995/3

N2 - Hepatitis B viral liver disease (HBVLD) is a major worldwide health problem. It is estimated over 300 million people have had hepatitis B virus infection and that one-third of these have chronic HBVLD. Little effective therapy exists for HBVLD even though high dose interferon (IFN) has been advocated. For those who either are untreated or do not respond to IFN, HBVLD is steadily progressive and orthotopic liver transplantation (OLTx) is the only available therapy. Until quite recently, all OLTx recipients received cyclosporine (CyA) and prednisone. The consequence of OLTx for HBV disease in individuals immunosuppressed with tacrolimus has not previously been reported. A total of 78 consecutive patients with HBV-related liver diseases who were transplanted between January 1, 1990, and December 31, 1991, and treated with tacrolimus were studied. The clinical records of these patients were reviewed retrospectively. HBV disease recurrence was documented with serologic and histologic methods. As of April 1, 1993, 57 of 78 (73%) of the patients were still alive. Thirty-one of the alive patients have documented HBV recurrence. Eighteen of these 31 patients, however, have normal liver function. With a median follow-up of 24 months, 8 patients (10.9%) have died of recurrent HBVLD. Seven of 8 patients, who preoperatively were HBeAg+, developed recurrence and 4 of these patients have already died of recurrence. Patients who were HBsAg+ rarely recurred (1 of 16 patients). The use of HBIG did not prevent recurrence.(ABSTRACT TRUNCATED AT 250 WORDS)

AB - Hepatitis B viral liver disease (HBVLD) is a major worldwide health problem. It is estimated over 300 million people have had hepatitis B virus infection and that one-third of these have chronic HBVLD. Little effective therapy exists for HBVLD even though high dose interferon (IFN) has been advocated. For those who either are untreated or do not respond to IFN, HBVLD is steadily progressive and orthotopic liver transplantation (OLTx) is the only available therapy. Until quite recently, all OLTx recipients received cyclosporine (CyA) and prednisone. The consequence of OLTx for HBV disease in individuals immunosuppressed with tacrolimus has not previously been reported. A total of 78 consecutive patients with HBV-related liver diseases who were transplanted between January 1, 1990, and December 31, 1991, and treated with tacrolimus were studied. The clinical records of these patients were reviewed retrospectively. HBV disease recurrence was documented with serologic and histologic methods. As of April 1, 1993, 57 of 78 (73%) of the patients were still alive. Thirty-one of the alive patients have documented HBV recurrence. Eighteen of these 31 patients, however, have normal liver function. With a median follow-up of 24 months, 8 patients (10.9%) have died of recurrent HBVLD. Seven of 8 patients, who preoperatively were HBeAg+, developed recurrence and 4 of these patients have already died of recurrence. Patients who were HBsAg+ rarely recurred (1 of 16 patients). The use of HBIG did not prevent recurrence.(ABSTRACT TRUNCATED AT 250 WORDS)

UR - http://www.scopus.com/inward/record.url?scp=0029269720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029269720&partnerID=8YFLogxK

M3 - Article

C2 - 7539077

AN - SCOPUS:0029269720

VL - 88

SP - 103

EP - 108

JO - The Journal of the Oklahoma State Medical Association

JF - The Journal of the Oklahoma State Medical Association

SN - 0030-1876

IS - 3

ER -